155 related articles for article (PubMed ID: 23019224)
1. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas.
Fukawa T; Ono M; Matsuo T; Uehara H; Miki T; Nakamura Y; Kanayama HO; Katagiri T
Cancer Res; 2012 Nov; 72(22):5867-77. PubMed ID: 23019224
[TBL] [Abstract][Full Text] [Related]
2. A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.
Daizumoto K; Yoshimaru T; Matsushita Y; Fukawa T; Uehara H; Ono M; Komatsu M; Kanayama HO; Katagiri T
Cancer Res; 2018 May; 78(9):2233-2247. PubMed ID: 29440146
[TBL] [Abstract][Full Text] [Related]
3. Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.
Chen J; Zhu H; Zhang Y; Cui MH; Han LY; Jia ZH; Wang L; Teng H; Miao LN
Mol Med Rep; 2015 Aug; 12(2):2622-8. PubMed ID: 25954860
[TBL] [Abstract][Full Text] [Related]
4. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.
García JF; Villuendas R; Sánchez-Beato M; Sánchez-Aguilera A; Sánchez L; Prieto I; Piris MA
Am J Pathol; 2002 Feb; 160(2):569-78. PubMed ID: 11839577
[TBL] [Abstract][Full Text] [Related]
5. p53 regulation and function in renal cell carcinoma.
Warburton HE; Brady M; Vlatković N; Linehan WM; Parsons K; Boyd MT
Cancer Res; 2005 Aug; 65(15):6498-503. PubMed ID: 16061625
[TBL] [Abstract][Full Text] [Related]
6. A redox mechanism underlying nucleolar stress sensing by nucleophosmin.
Yang K; Wang M; Zhao Y; Sun X; Yang Y; Li X; Zhou A; Chu H; Zhou H; Xu J; Wu M; Yang J; Yi J
Nat Commun; 2016 Nov; 7():13599. PubMed ID: 27886181
[TBL] [Abstract][Full Text] [Related]
7. Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders.
Calo E; Gu B; Bowen ME; Aryan F; Zalc A; Liang J; Flynn RA; Swigut T; Chang HY; Attardi LD; Wysocka J
Nature; 2018 Feb; 554(7690):112-117. PubMed ID: 29364875
[TBL] [Abstract][Full Text] [Related]
8. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.
Gurova KV; Hill JE; Razorenova OV; Chumakov PM; Gudkov AV
Cancer Res; 2004 Mar; 64(6):1951-8. PubMed ID: 15026329
[TBL] [Abstract][Full Text] [Related]
9. MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.
Polanski R; Maguire M; Nield PC; Jenkins RE; Park BK; Krawczynska K; Devling T; Ray-Sinha A; Rubbi CP; Vlatkovic N; Boyd MT
Carcinogenesis; 2011 Aug; 32(8):1133-42. PubMed ID: 21504894
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
11. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
12. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
14. Gradual reduction in rRNA transcription triggers p53 acetylation and apoptosis via MYBBP1A.
Kumazawa T; Nishimura K; Katagiri N; Hashimoto S; Hayashi Y; Kimura K
Sci Rep; 2015 Jun; 5():10854. PubMed ID: 26044764
[TBL] [Abstract][Full Text] [Related]
15. PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
Bernardi R; Scaglioni PP; Bergmann S; Horn HF; Vousden KH; Pandolfi PP
Nat Cell Biol; 2004 Jul; 6(7):665-72. PubMed ID: 15195100
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
[TBL] [Abstract][Full Text] [Related]
17. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
18. Perturbation of ribosome biogenesis drives cells into senescence through 5S RNP-mediated p53 activation.
Nishimura K; Kumazawa T; Kuroda T; Katagiri N; Tsuchiya M; Goto N; Furumai R; Murayama A; Yanagisawa J; Kimura K
Cell Rep; 2015 Mar; 10(8):1310-23. PubMed ID: 25732822
[TBL] [Abstract][Full Text] [Related]
19. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
Ding L; Zhang Z; Zhao C; Chen L; Chen Z; Zhang J; Liu Y; Nie Y; He Y; Liao K; Zhang X
J Exp Clin Cancer Res; 2021 Aug; 40(1):245. PubMed ID: 34362424
[TBL] [Abstract][Full Text] [Related]
20. RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Yu S; Dai J; Ma M; Xu T; Kong Y; Cui C; Chi Z; Si L; Tang H; Yang L; Sheng X; Guo J
Cell Death Dis; 2019 Mar; 10(4):254. PubMed ID: 30874541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
